We observed that patients with higher CTNNAL1 had much poorer progression-free survival (n = 69; median survival, 19 months) than those showing lower CTNNAL1 levels (n = 56; median survival, 34.8 months), suggesting that expression of α-Catulin correlates with clinical outcomes of chemotherapy in patients with lung cancer (Figure 2G). The gene discussed is CTNNAL1; the disease is lung carcinoma.